FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 408 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Targeted Therapy Cabozantinib Slows Progression of Rare Kidney Cancer March 24, 2021 Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC... June 30, 2023 New targeted lung cancer screening programme on the horizon September 29, 2022 Determining Fluid Requirements March 26, 2021 Load more HOT NEWS World No Tobacco Day 2024: European Societies call for an EU... 9 Ways to Use Social Media for Support Throughout Your Cancer... How Are Eligibility Criteria for Clinical Trials Changing to Help People... EMA Recommends Extension of Indications for Durvalumab
